

Gastroenterology

Volume 170 / Issue 4

April 2026

www.gastrojournal.org

TABLE OF
CONTENTS

Contents

ON THE COVER

Gastroenterology



Genetic Risk of IBD and Disease Course Severity. See article by Vestergaard, et al, page 721 for additional information.

IN MEMORIAM

657 In Memoriam: Brian G. Feagan, MD, FRCPC (1954–2025)

R. Panaccione, G. R. D'haens, B. E. Sands, J. W. D. McDonald, R. Khanna, V. Jairath, J. G. Fletcher, D. Bruining, M. E. Baker, C. Ma, F. Rieder, and W. J. Sandborn

COMMENTARIES

660 Perspectives on the Issues of Indeterminate/Gray Zones of Chronic Hepatitis B Virus Infection

Y.-F. Liaw and C.-M. Chu

665 CD19 CAR T-Cell Therapy for Refractory Ulcerative Colitis

I. Marafini, S. Salvatori, E. Troncone, and G. Monteleone

MENTORING, EDUCATION, AND TRAINING CORNER

668 Enhanced Trainer Performance and Resident Learning Following Implementation of a Training the Colonoscopy Trainers Course

R. A. Mousset, W. H. de Vos tot Nederveen Cappel, J. J. Boonstra, J. C. H. Hardwick, J. van der Kraan, J.-P. E. N. Pierie, P. L. P. Brand, and A. M. J. Langers

GASTRO CURBSIDE CONSULT

674 An Atypical Presentation of a Typical Pancreatic Cyst

K. Chandrasekaran, N. Assarzadegan, and P. V. Draganov

678 From Ongoing Fibrosis to Biopsy to Diagnosis: A Thorough Evaluation of Liver Granulomas in Clinical Practice

J. A. Benitez, A. G. Aldana, and L. D. Pedicone

Video

Related article in CGH

Hot Papers From New Investigators

CME quiz

Editorial accompanies this article

Additional online content available

Cover

Publisher: *Gastroenterology* (ISSN 0016-5085) is published monthly (semi-monthly in April) in two indexed volumes by Elsevier Inc., 1818 Market Street, Philadelphia, PA 19103, United States. Periodicals postage paid at New York, NY and additional mailing offices. POSTMASTER: Send address changes to Elsevier, Journal Returns, 450 Fame Avenue, Hanover, PA 17331, USA. 2026 US subscription rates: individual, \$848.00; student and resident, \$323.00. Outside of the U.S. and possessions: individual, \$1026.00; student and resident, \$596.00; surface delivery, no additional charge; air mail delivery, add \$78.00. Prices subject to change without notice.

682 Uncovering the Real Causes Behind Anemia

X. Jia, J. Yu, and M. Jiang

REVIEWS IN BASIC AND CLINICAL GASTROENTEROLOGY AND HEPATOLOGY

686 Toward Integration of Molecular Measures and Artificial Intelligence-Based Assessments With Clinical End Points in Inflammatory Bowel Disease

W. Reinisch, J. Rittscher, M. Iacucci, S. Travis, and M. Friedrich

ORIGINAL RESEARCH

Full Reports

Inflammatory Bowel Disease

704 **Faecalibacterium prausnitzii** Induces an Anti-inflammatory Response and a Metabolic Reprogramming in Human Monocytes

www

C. Danne, R. de Oliveira Formiga, L. Creusot, F. Marquet, D. Sedda, L. Hua, P. Ruffié, H.-P. Pham, L. Brot, I. Alonso Salgueiro, M.-L. Michel, P. Langella, J. H. Lefevre, H. Sokol, and N. Rolhion

Faecalibacterium prausnitzii EXL01 strain directly induces interleukin 10 production by cluster of differentiation 14-positive human monocytes and reprograms the energy metabolism of these cells under both healthy and inflammatory conditions.

721 **Genetic Risk of Inflammatory Bowel Disease Is Associated With Disease Course Severity**

www cov

M. V. Vestergaard, K. H. Allin, A. K. Nøhr, J. V. Torresano Lominchar, H. S. Christensen, H. Krarup, K. R. Nielsen, H. A. Jacobsen, J. Bybjerg-Grauholm, M. Bækvad-Hansen, R. F. Brøndum, M. Bøgsted, L. Larsen, A. Sazonovs, and T. Jess

This study on an unselected population-based Danish cohort found that a larger genetic burden for developing inflammatory bowel disease also increases the risk of having a subsequent severe disease course.

Pancreas

735 **ENPP1-Regulated Extracellular Purine Metabolism Drives Pancreatitis-Mediated Pancreatic Cancer**

www

Z. Ma, M. Dong, H. Pan, J. Xu, T. Luo, W. Xie, M. Xiao, X. Wen, J. Hua, D. Qian, Q. Meng, Y. Wang, D. Wu, X. Zhang, T. Yang, Z. Song, W. Wang, J. Xu, X. Yu, and S. Shi

Ectonucleotide pyrophosphatase/phosphodiesterase 1-regulated extracellular purine metabolism drives pancreatitis-mediated pancreatic cancer, presenting a potential therapeutic target for immunotherapy in pancreatic cancer and early intervention in pancreatitis-cancer transformation.

753 **Depletion of Fibrinogen Suppresses Growth of Primary Tumors and Metastasis of Pancreatic Ductal Adenocarcinoma**

www

N. N. Chowdhury, D. K. Mitchell, K. Kangro, K. Eldridge, S. Abrahams, F. Ferraresso, L. J. Juang, S. Gampala, K. Brewster, A. Revenko, C. Kastrup, P. R. Territo, D. W. Clapp, J. Wang, J. A. Belgodere, O. Saeed, S. R. Choi, B. Han, A. S. Wolberg, S. Cao, C. Zhang, M. J. Flick, and M. L. Fishel

Depleting a wound-healing protein, fibrinogen, limits tumor growth and metastasis in pancreatic ductal adenocarcinoma, suggesting fibrinogen targeted therapy will help control the spread of pancreatic cancer.

769 **Single-Cell Analysis of Chemotherapy-induced Remodeling Reveals CD276-driven Basal-like Chemoresistance in Pancreatic Cancer**

www

Y. Zhang, Y. Du, J. Wang, D. Wang, J. Li, J. Zhang, Y. Zhao, S. Sun, H. Sun, J. Qi, R. Bao, C. Shao, M. Zhang, X. He, L. Zhang, C. Zhou, D. Wang, B. Su, D. Zou, and Y. Ye

This work reveals the plasticity of pancreatic ductal adenocarcinoma tumor cell states and their interactions with the tumor microenvironment during chemotherapy, highlighting CD276/B7-H3 as a key regulator and promising therapeutic target for overcoming chemotherapy resistance.

Hepatobiliary

787 **Overcoming CXCR4-Mediated T-Cell Exclusion Potentiates Antitumor Cytotoxicity in Fibrolamellar Carcinoma**

J. A. Carter, L. K. Dickerson, A. Stephanou, S. R. Damle, K. E. Goodsell, S. K. Daniel, K. M. Sullivan, B. Shui, X. Jiang, H. L. Kenerson, R. J. E. van den Bijgaart, A. R. Farghli, Y. Liu, E. Beirne, K. P. Labadie, J. Cernak, S. S. B. Chauhan, J. M. Bello Pineda, A. N. Long, A. E. Elz, E. W. Newell, T. S. Kim, K. J. Riehle, R. S. Yeung, S. Akilesh, I. N. Crispe, K. C. Barry, P. Sethupathy, and V. G. Pillarisetty

Fibrolamellar carcinoma is a rare liver cancer with limited systemic treatment options. This study identifies CXCR4 chemokine signaling as a key driver of immune exclusion in fibrolamellar carcinoma. Therapeutically targeting CXCR4 potentiates PD-1 blockade, together representing a new combination immunotherapy approach.

803 **Prognostic Performance of Phosphatidylethanol With Noninvasive Liver Fibrosis Tests in Alcohol-Related Liver Disease**

N. Torp, S. Johansen, E. L. Jensen, M. Maagaard, G. Semmler, M. L. Andersen, K. Bech, H. Schnefeld, K. P. Lindvig, K. H. Thorhauge, E. E. Petersen, J. K. Hansen, I. F. Villesen, P. Andersen, M. L. Bergmann, D. J. Leeming, M. Karsdal, C. D. Hansen, M. Thiele, M. Israelsen, and A. Krag

Phosphatidylethanol, an accurate blood-based biomarker of past 4 weeks' alcohol intake, predicts hepatic decompensation independently of noninvasive liver fibrosis tests in individuals at risk of alcohol-related liver disease.

RESEARCH LETTERS

815 **The Human Blood Virome Differs in Crohn's Disease**

Q. Lamy-Besnier, I. Theodorou, H. Sokol, M. De Paepe, M.-A. Petit, L. De Sordi, and Blood Virome Working Group

818 **Involvement of Eosinophil-Driven Intestinal Immune Activation in Different Irritable Bowel Syndrome Subtypes and in the Response to a FODMAP Lowering Diet: A Post Hoc Analysis of the Randomized Controlled DOMINO Trial**

K. Routhiaux, L. M. Balsiger, M. Ceulemans, T. Vanuytsel, J. Tack, K. Van Den Houte, and DOMINO Working Group

821 **Genomic Dissection of Pediatric Protein-Losing Enteropathy and Related Disorders: Clinical, Immunologic, and Therapeutic Insights**

A. P. Sefer, B. Erman, S. Baris, E. Karakoc-Aydiner, The PLE Working Group, B. Lo, and A. Ozen

826 **Long-Term, Prospective Assessment of Cancer Risk in APC c.3920T>A (I1307K) Carriers: Evidence From a Cohort of Over 21,000 Healthy Individuals**

Y. Hoffman, A. Eshel Fuhrer, M. Levy, D. Kazanov, N. Arber, and S. Shapira

AGA SECTION

829 **Multi-Society Expert Panel Consensus Guidance Regarding Clinical Assessment and Clinical Trial Endpoints in Adults With Alpha-1 Antitrypsin Deficiency-Associated Liver Disease**

R. Loomba, V. C. Clark, M. Mandorfer, M. Miravittles, M. Brantly, S. J. Karpen, A. Krag, P. Y. Kwo, D. C. Rockey, M. W. Russo, A. J. Sanchez, S. Santarella, S. R. Sharpton, C. Strange, J. H. Teckman, A. M. Turner, H. E. Vargas, and P. Strnad

Experts developed new guidance to help physicians recognize and monitor liver disease in people with alpha-1 antitrypsin deficiency using simple blood and imaging tests.

GASTRO DIGEST

843 **Exploring the Differential Impact of Steatotic Liver Disease Phenotypes Upon Clinical Outcomes**

B. H. Mullish

844 **GERD and Its Complications Associated With GLP-1 Receptor Agonists**

M. Hanscom

- 844 Tiptoeing in From the Fatty Fringes: Mechanosensitive Fibroblasts and Crohn's Disease**
J. R. Thiagarajah
- 845 Profiling the Enteric Nervous System**
D. Reed
- CORRESPONDENCE**
- 847 Sham Limits, Narrow Benefits: Re-Examining the ACTION Acupuncture Trial in IBS-D**
T. Zhang
- 848 Beyond Short-Term Relief: Rethinking Time Horizons in IBS Acupuncture Trials**
Z. Chen, X. Cai, and H. Jiang
- 849 Blurring the Line Between Control and Treatment: Reconsidering Sham Acupuncture in IBS Trials**
M.-J. Wang and F. Chen
- 849 Methodological Comments on "Efficacy of ACupuncTure in Irritable bOwel syNdrome (ACTION): A Multicenter Randomized Controlled Trial"**
S. Lin, P. Shen, Y. Wan, and C. Wang
- 850 Comment on "Efficacy of ACupuncTure in Irritable bOwel syNdrome (ACTION): A Multicenter Randomized Controlled Trial"**
M. Zhang
- 851 Reply**
J.-W. Yang, N.-N. Yang, and C.-Z. Liu
- 852 Refining Meta-Analyses of GLP-1RA Safety: Sparse Event Data, Confounding, and Sex Differences**
J. Huang
- 853 Reply**
Y. P. Hsia, C.-H. Chiang, and C.-H. Chiang
- 854 Celiac Disease Diagnosis on a Gluten-Free Diet: Unresolved Issues**
C. Núñez, S. Gómez-Aguililla, and N. López-Palacios
- 855 Reply**
O. G. Moscatelli, M. Y. Hardy, and J. A. Tye-Din
- 856 Comments on Hepatic Stellate Cell Regulation in Metabolic Dysfunction-Associated Steatohepatitis**
S. M. Ali
- 857 Reply**
D. A. Brenner

- 857 Limitations and Implications for Barrett's Esophagus Surveillance**
G. Yan
- 858 Reply**
O. Old, P. Moayyedi, and H. Barr
- 859 Comment on "Cost-Effectiveness of Regular Surveillance Versus Endoscopy at Need for Patients With Barrett's Esophagus: Economic Evaluation Alongside the Barrett's Oesophagus Surveillance Study (BOSS) Randomized Controlled Trial"**
Z. Zhuang, L. Jiang, Y. Kang, and H. Chi
- 860 Revising the Model for Accurate Cost-Effectiveness of Barrett's Esophagus Surveillance**
S. Li

Access to the full content of Gastroenterology Online is available to all subscribers!

AGA members have seamless access to full *Gastroenterology* content from the AGA Web site. Simply sign in to <http://www.gastro.org>, visit the Publications section of the Web site, and click on *Gastroenterology*. You will be directed to the Journal Web site and will have full access to all content without having to supply a different username and password. Members can also visit <http://www.gastrojournal.org> directly and click on "Activate Online Access." Nonmember subscribers must create an online user account and activate their subscription to access the full text of articles on *Gastroenterology* Online. To activate your individual online subscription, please visit <http://www.gastrojournal.org> and click on "Activate Online Access." To activate your account, you

will need your subscriber account or member number, which you can find on your mailing label, (AGA members must use their 10-digit member number, including leading zeros). If you have any questions regarding your online subscription please call Elsevier Customer Service at (800) 654-2452.

Institutional access to *Gastroenterology* Online will be allowed only by limited site licensing. Further instructions will be available online. Personal subscriptions to *Gastroenterology* Online are for individual use only and may not be transferred. Use of *Gastroenterology* Online is subject to agreement to the terms and conditions of use as indicated online.

AGA Member Number

Your Account Number

Sample
mailing
label

GAST0000101864
JANE DOE
531 MAIN ST
CENTER CITY, NY 10001-001

1GAST V91-4 1234567-8
JANE DOE
531 MAIN ST
CENTER CITY, NY 10001-001